A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Trial ID or NCT#
NCT04697056
Status
Purpose
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
Eligibility Criteria
Ages Eligible for Study: 12 Years to 75 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Diagnosis of Ichthyosis* IASI total score ≥ 18, erythema score ≥ 2* Participant has been using emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily at the same frequency throughout the study
Exclusion Criteria:
- * A participant with ichthyosis vulgaris, X-linked ichthyosis, or lamellar ichthyosis will be excluded.
Investigator(s)
Joyce Teng, MD, PhD
Dermatologist,
Pediatric dermatologist
Professor of Dermatology and, by courtesy, of Pediatrics
View on ClinicalTrials.gov